Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
MAGEA3 is a member of the MAGEA gene family. Additionally we are shipping MAGEA3 Proteins (10) and MAGEA3 Kits (3) and many more products for this protein.
Showing 10 out of 89 products:
Human Polyclonal MAGEA3 Primary Antibody for FACS, IHC (p) - ABIN390107
Guo, Wen, Huang, Paul, Wünsch, Itakura, Cochran: Detection of multiple melanoma-associated markers in melanoma cell lines by RT in situ PCR. in Experimental and molecular pathology 2003
Show all 7 Pubmed References
Human Polyclonal MAGEA3 Primary Antibody for EIA, IHC (p) - ABIN303466
Yin, Zeng, Wang, Liu, Zhang, Song: Expression and clinical significance of cancer-testis genes in clear cell renal cell carcinoma. in International journal of clinical and experimental pathology 2014
Human Monoclonal MAGEA3 Primary Antibody for ELISA, WB - ABIN561731
Akiyama, Oshita, Kume, Iizuka, Miyata, Komiyama, Ashizawa, Yagoto, Abe, Mitsuya, Watanabe, Sugino, Yamaguchi, Nakasu: ?-type-1 polarized dendritic cell-based vaccination in recurrent high-grade glioma: a phase I clinical trial. in BMC cancer 2013
Human Polyclonal MAGEA3 Primary Antibody for IHC, IHC (p) - ABIN4890850
Abad, Wieërs, Colau, Wildmann, Delair, Dhote, Brézin, Kawakami, Coulie, van der Bruggen: Absence of recognition of common melanocytic antigens by T cells isolated from the cerebrospinal fluid of a Vogt-Koyanagi-Harada patient. in Molecular vision 2014
the objective response rate was lower in this study than in other studies carried out in the same setting with the MAGE-A3 immunotherapeutic. Investigation of a gene signatures (GS) to predict clinical benefit to adjuvant MAGE-A3 immunotherapeutic treatment is ongoing in another melanoma study.
Administering autologous CD4 (show CD4 Antibodies)(+) T cells that are genetically engineered to express an MHC class II (show HLA-DPA1 Antibodies)-restricted antitumor TCR that targets MAGE-A3 can be used safely in the treatment of metastatic neoplasms.
Data show that overall survival (OS) was significantly lower for patients expressing pan (show SUPT6H Antibodies)-MAGE (show MAGEB10 Antibodies) or MAGE (show MAGEB10 Antibodies)-A1/A3/A4 in both independent cohorts.
These data demonstrate that MAGE (show MAGEB10 Antibodies)-A1-, MAGE-A3-, and NY-ESO-1 (show CTAG1B Antibodies)-specific T cells with antigen-specific cytotoxicity can be cultured from healthy donors and patient-derived cells making adoptive immunotherapy with these cytotoxic T lymphocyte feasible.
MAGEA3 may be demethylated in MPNST and plexiform type neurofibroma in NF-1 (show NF1 Antibodies) patients
MAGEA3 was overexpressed in colorectal cancer tissue compared with healthy colon. MAGEA3 expression positively correlated with colorectal cancer progression.
Comparing the overall expression of CTAs, a decreased expression of all melanoma-associated (show ZNF654 Antibodies) antigens (MAGEs) post-treatment and a slightly increased expression of New York esophageal squamous cell carcinoma 1 (NY-ESO-1 (show CTAG1B Antibodies)) was visible. The simultaneous cytoplasmic and nuclear expression of pan (show SUPT6H Antibodies)-MAGE (show MAGEB10 Antibodies) or MAGE-A3/A4 correlated with reduced treatment-failure-free-survival (TFFS).
MAGE-A3 expression is regulated epigenetically by promoter methylation, and that its expression contributes to gastric cell proliferation and drug sensitivity.
Progression free survival and levels of MAGE-A3 expression in non-small cell lung carcinoma patients with the three modes of acquired resistance are negatively correlated.
the crystal structures of MAGE-A3 and MAGE-A4 (show MAGEA4 Antibodies)
This gene is a member of the MAGEA gene family. The members of this family encode proteins with 50 to 80% sequence identity to each other. The promoters and first exons of the MAGEA genes show considerable variability, suggesting that the existence of this gene family enables the same function to be expressed under different transcriptional controls. The MAGEA genes are clustered at chromosomal location Xq28. They have been implicated in some hereditary disorders, such as dyskeratosis congenita.
, antigen MZ2-D
, cancer/testis antigen 1.3
, cancer/testis antigen family 1, member 3
, melanoma-associated antigen 3
, melanoma antigen family A, 3